Assessment superseded
Metformin effects on prostate cancer biology tested in randomized controlled trial
The METAL study was a randomized, placebo-controlled, double-blind window of opportunity trial examining metformin's biological effects in localized prostate cancer. No results, effect sizes, or sample size details were reported in the available material.
RCTMinor significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Jul 30, 2015 · Discovered: Sep 15, 2026 · Assessed: — · Research update
What it does not prove
- Limitations have not yet been verified. Read the primary source.
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- —
- Population
- Patients with localised prostate cancer
- Primary outcome
- Biological mechanism of metformin in prostate cancer (inferred from title; specific biomarkers not specified in abstract)
- Effect size
- —
- Significance
- Not reported
- Journal
- Guy's and St Thomas' NHS Foundation Trust
- Published
- Jul 30, 2015
Sources
Primary source
- Guy's and St Thomas' NHS Foundation Trust ↗Clinical trial
Source versions
Assessment history
9/23/2026 · SUPERSEDED: Source updated; assessment withdrawn pending review.
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.